Ventoux Biosciences

Ventoux Biosciences was founded by a Dupuytren's, Ledderhose, and Garrod's Knuckle Pad patient with a mission to revolutionize treatment for these common, progressive, debilitating, yet under-served diseases. Ventoux Biosciences is a biopharmaceutical company focused on acquiring, in-licensing, developing, and commercializing proprietary products for Dupuytren's Disease and related immuno-fibrotic and inflammatory conditions with significant unmet medical need. Currently, Ventoux Bioscience's is working to advance development of VEN-201 as the lead compound following positive pre-clinical research.